EN

EN

CN

About Us

FRONTERA THERAPEUTICS

Frontera is a clinical-stage biotech company dedicated to bringing innovative, high-quality, affordable rAAV gene therapies to patients worldwide.


With R&D centers, clinical operations, and GMP manufacturing facilities in Boston (USA), Shanghai, and Suzhou (China), we have built a world-class drug discovery and development team. Our work is backed by leading academic and industry experts and supported by renowned venture capital firms.

 

We have developed innovative gene therapies pipeline to address significant unmet medical needs in both large and rare diseases in ophthalmology, hematology and cardiology. Several programs have  entered or completed Phase II clinical trials, demonstrating "Best-in-Class" potential with strong competitive advantages.

 

Our R&D center has established a robust technology platform for AAV capsids and gene expression cassette engineering. Through a comprehensive in vitro and in vivo screening process, we have secured patent-protected AAV vectors that offer precise tissue targeting, more durable gene transduction, and potentially lower immunogenicity.

 

The company has developed a comprehensive Sf9 insect cell-baculovirus expression vector system (Sf9 BEVS) and operates a state-of-the-art AAV GMP manufacturing facility with a fully integrated quality control system. Our robust, scalable production and purification processes - together with a comprehensive analytical assay platform - achieve industry-leading yields while establishing a new benchmark for low empty capsid levels. By significantly reducing the cost of goods sold (COGS), our manufacturing platform enables greater patient access and affordability.

Key Milestone

2019

Founded by OrbiMed and Creacion Ventures, raising $35M in Series A financing.

2020

Established an R&D team in Boston, USA.

Initiated operations in Shanghai, China.

Registered GMP manufacturing in Suzhou, China.

2021

Opened the Boston R&D center.

Completed the Suzhou GMP facility.

Closed a $160M Series B financing led by Boyu Capital and Sequoia China, with participation from Loyal Valley Capital and Starr Investment.

2022

Received IND clearance for FT-001 in both the U.S. and China.

2023

Secured four additional IND clearances for clinical trials in China.

Launched six clinical studies, including three Phase I trials and three IITs.

Completed the Phase I trial of FT-001 and initiated a Phase II study.

2024

Concluded a Phase II trial for one program in China.

Advanced three programs into Phase II trials in China.

Received three FDA IND clearances for Phase II trials in the U.S

2019
2020
2021
2022
2023
2024